SMU-R39

• Description:

  SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 μM and 0.24 μM, respectively. SMU-R39 binds to recombinant mTLR7 protein (KD = 2.36 μM) and to recombinant hTLR8 protein (KD = 105 nM) . SMU-R39 suppresses downstream NF-κB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ) (HY-B0180) -induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis[1].

• UNSPSC:

  12352005

• Target:

  NF-κB; p38 MAPK; Toll-like Receptor (TLR)

• Related Pathways:

  Immunology/Inflammation; MAPK/ERK Pathway; NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  OC1=CC=C(N2C=NC3=C2C4=CC=CC=C4N=C3N5CCN(CC)CC5)C=C1C

• Molecular Formula:

  C23H25N5O

• Molecular Weight:

  387.48

• References & Citations:

  [1]Wu P, et al. Structure-based rational design of TLR7/8 antagonists through agonist scaffold reengineering for psoriasis therapy. Eur J Med Chem. 2025 Dec 5;299:118063.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  TLR7; TLR8